CLRB - Cellectar Biosciences, Inc.

2.75
-0.010   -0.364%

Share volume: 114,458
Last Updated: 03-09-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.20%

PREVIOUS CLOSE
CHG
CHG%
$2.76
-0.01
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 25%
Dept financing 6%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.72%
1 Month
-17.66%
3 Months
-31.59%
6 Months
-45.00%
1 Year
772.74%
2 Year
-27.06%
Key data
Stock price
$2.75
P/E Ratio 
N/A
DAY RANGE
$2.64 - $2.95
EPS 
-$6.97
52 WEEK RANGE
$0.23 - $10.19
52 WEEK CHANGE
$779.44
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
4.240 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-13-2025
BETA 
1.98
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$72,606
AVERAGE 30 VOLUME 
$35,950
Company detail
CEO: James V. Caruso
Region: US
Website: cellectar.com
Employees: 10
IPO year: 2005
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Cellectar Biosciences, Inc. focuses on the discovery, development, and commercialization of drugs for cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies.

Recent news